Lynch Syndrome and Cancer Interception: Why Vaccine Trials Are Closely Watched

Trying to stop a cancer before it starts

Most cancer vaccines in the news treat existing disease. A smaller set aims at something harder. They try to teach the immune system to recognize the earliest changes in a person who does not have cancer yet.

Lynch syndrome is where this idea is being tested first, and the reason is practical. The population is identifiable through genetic testing, the risk is high, and the biology of the earliest changes is relatively well understood.

None of that means a preventive vaccine works. These are early trials.

This page explains public sources. It is not medical advice and does not suggest a test or treatment.

What Lynch syndrome is

NCI describes Lynch syndrome as an inherited disorder that raises the risk of colorectal cancer, endometrial cancer, ovarian cancer, and many other types. Those include cancers of the stomach, small intestine, pancreas, bile duct, urinary tract, and brain. They often appear before age 50.

The cause is a change in one of five genes that handle DNA mismatch repair: MLH1, MSH2, MSH6, PMS2, and EPCAM. That repair system fixes mistakes made when DNA is copied. When it fails, errors accumulate.

NCI's Division of Cancer Prevention reports that Lynch syndrome affects about 1 in 279 people, roughly 1.1 million in the United States. It is the most common cause of hereditary colorectal cancer.

Risk is not uniform across that group. It varies by which gene is affected, by organ, by age, and by family. Our overview of Lynch syndrome covers that variation, and genetic testing for cancer risk explains how the diagnosis is made.

What the trials are actually testing

NCI described two experimental approaches in 2023. They work differently, which is part of why both are being studied.

The Nous-209 vaccine takes what investigators called a brute force approach. It contains 209 fragments of cancer-specific neoantigens found in premalignant or malignant tissue in people with Lynch syndrome, with the aim of provoking a strong immune response.

The Tri-Ad5 vaccines came out of NCI's own intramural program. They use three tumor-associated antigens that are overexpressed in cancer cells but also present at lower levels in healthy tissue. Early work with one antigen, MUC-1, looked promising, so CEA and brachyury were added. The regimen is paired with an interleukin-15 stimulant.

The goal, as one investigator put it, is to train the immune system to recognize early signals of tumor development and disrupt them.

Phase 1 answers a narrow question

The Nous-209 study is a phase 1 trial. It assesses safety and immunogenicity, meaning whether the vaccine produces an immune response at all.

That is not the same as preventing cancer. An immune response is a biological signal that something happened. It does not establish that a tumor was stopped.

The trial is open to people who test positive for a mutation in one of the five mismatch repair genes and who remain cancer-free. As of January 2023, it had enrolled 10 participants toward a goal of 45, with sites in California, Pennsylvania, Texas, and Puerto Rico.

Those numbers are worth sitting with. A first-participant or first-dose announcement contains no evidence that a vaccine works. Our page on cancer vaccines for prevention explains where this field currently stands.

Why prevention trials are slow

Testing prevention is harder than testing treatment, for reasons built into the design.

• Participants are healthy. Safety standards must be higher, because harm is not offset by treating existing disease.
• The outcome of interest may occur years later, or not at all.
• Many participants will never develop the target cancer, which makes any difference hard to detect.
• Proven measures such as colonoscopy and preventive surgery continue during the study, and they change how many cancers occur.

That last point cuts both ways. Continuing surveillance is ethically required. It also makes the vaccine's own effect harder to isolate.

What surveillance still does

Genetic counseling, family testing, and recommended surveillance are established parts of care for Lynch syndrome. Colonoscopy at shortened intervals is the clearest example, and it both detects cancer early and removes polyps before they progress.

An experimental vaccine does not replace any of that, during a trial or after it.

Questions about a prevention trial

• Which Lynch gene and which cancer risks does this trial address?
• What standard surveillance continues during the study?
• Does the trial measure immune markers, precancerous changes, cancer cases, or all three?
• How long will participants be followed after the last dose?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.